SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits shares are under pressure after the FDA issued a Complete Response Letter for ivonescimab, saying the application lacked a statistically significant overall-survival benefit. Traders debate whether the strong progression-free-survival results and improving survival trend support the drugs longer-term prospects, while others see the decision as a major setback because the FDA had identified overall survival as a requirement.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and volatile rebound from recent support dominate the discussion, with traders debating whether the bounce marks a bottom or is only a pause before further losses. Many point to oversold conditions and leveraged liquidations, while others warn that selling pressure could continue.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

A nationwide FAA communications outage is drawing scrutiny to L3Harris after officials said a company-managed router may have overwhelmed the system; investigators have not determined whether equipment defects or installation errors caused the failure, and cyberattack claims remain speculation. Traders debate whether L3Harris is being unfairly blamed or could face consequences, with bearish calls and short interest talk countered by dip-buying interest.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,079,921,637.950731 in circulation. The last known price of Algorand is 0.07697008 USD and is down -9.60 over the last 24 hours. It is currently trading on 586 active market(s) with $68,192,697.70 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

Algorands steep decline toward long-term lows and a weak bounce have fueled debate over whether support is forming or the selloff will continue. Bulls point to a possible double-bottom retest and are accumulating, while bears warn that resistance and weak momentum could lead to further losses.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxiss Investor Day and launch preparations for ulixacaltamide in essential tremor and relutrigine in developmental epileptic encephalopathies are driving discussion, alongside upcoming FDA decisions and expected EMERALD trial results. Traders are enthusiastic about the drugs commercial potential, while some debate approval timing, pricing and how quickly launches could gain traction.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

A nationwide FAA ground stop caused by an air-traffic-control communications outage is weighing on Delta and other airline stocks, with ongoing delays and cancellations raising concern about operational and earnings impacts. Traders are divided between expecting further pressure and viewing the disruption as temporary now that the ground stop has been lifted; claims of deliberate or cyber-related causes remain speculation.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,752,062,860.16806072. The last known price of Dogecoin is 0.05689686 USD and is down -11.89 over the last 24 hours. It is currently trading on 1545 active market(s) with $1,128,721,930.78 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a broad crypto selloff, with traders focused on its steep decline, broken support, and lows not seen in years. The community is split between buying the dip and expecting more downside, with some pointing to Bitcoins weakness as broader market context.

Worldcoin (WLD) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Worldcoin has a current supply of 10,000,000,000 with 3,785,317,463.598902 in circulation. The last known price of Worldcoin is 0.25340812 USD and is down -14.02 over the last 24 hours. It is currently trading on 594 active market(s) with $288,215,183.49 traded over the last 24 hours. More information can be found at https://worldcoin.org/.

Worldcoin

Worldcoins volatile rebound is being linked by traders to OpenAIs reported confidential IPO filing and the broader proof-of-humanity narrative as AI agents proliferate. Others caution that WLD is not OpenAI equity and view the IPO connection as speculative, while some point to Arthur Hayess reported selling as a bearish signal.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Traders are using SCO, a leveraged inverse-crude ETF, to wager on oils direction amid Iran- and Strait of Hormuz-related supply disruptions and shifting expectations for de-escalation or restored flows. Views are divided between a potential oil decline and further supply-driven gains, while many holders complain that futures-curve effects and daily-reset decay have made SCOs performance fall short of their expectations.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel pushed its planned prostate-cancer BLA filing for aglatimagene to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff; a new at-the-market share-sale facility adds dilution concerns. Some investors view the delay as a CMC hurdle that does not undermine the Phase 3 results, while others question managements execution and transparency and worry about prolonged cash burn.

statis crypto Watchlist

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
